Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drugEmilia Alors‐Pérez, Justo P. Castaño, Ricardo Blázquez‐Encinas et al.|Journal of Experimental & Clinical Cancer Research|2021Cited by 60
Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivityQuan Zheng, Christopher Heeschen, Chiara Reina et al.|Journal of Experimental & Clinical Cancer Research|2023Cited by 17
Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drugEmilia Alors‐Pérez, Justo P. Castaño, Ricardo Blázquez‐Encinas et al.|Research Square|2021Cited by 2